Preview

User

Not a user? Register with this site Forgot your password?

PULMONOLOGIYA

Advanced search

Federal guidelines on diagnosis and treatment of chronic bronchitis

https://doi.org/10.18093/0869-0189-2022-32-3-448-472

Abstract

The presented clinical guidelines cover current information about the etiology and pathogenesis, classification, clinical manifestations, diagnosis, treatment, and prevention of chronic bronchitis.

Methodology. The target audience of these clinical guidelines are therapists, general practitioners, and pulmonologists. Each thesis-recommendation about diagnostic and therapeutic procedures has been graded according to the scales of classes of recommendations from 1 to 5 and the A, B, C scale for the levels of evidence. The clinical guidelines also contain comments and explanations to these theses together with an algorithm for management of patients with confirmed chronic bronchitis.

Conclusion. The presented clinical guidelines for the diagnosis and treatment of chronic bronchitis were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2021. 

About the Authors

S. N. Avdeev
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation

Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine, ul. Trubetskaya 8, build. 2, Moscow, 119991;

Leading Researcher, Orehovyy bul’var 28, Moscow, 115682


I. V. Demko
Federal State Budgetary Educational Institution of Higher Education “Prof. V.F.Voino-Yasenetsky Krasnoyarsk State Medical University”, Ministry of Healthcare of the Russian Federation
Russian Federation

Doctor of Medicine, Professor, Head of Department of Internal Medicine No.2 with Postgraduate Physician Training Course, 

ul. Partizana Zheleznyaka 1, Krasnoyarsk, 660022


A. A. Zaytsev
Main Military Clinical Hospital named after academician N.N.Burdenko, Ministry of Defense of the Russian Federation
Russian Federation

Doctor of Medicine, Professor, Chief Pulmonologist,

Gospital’naya pl. 3, Moscow, 105229


G. L. Ignatova
South Ural State Medical University, Healthcare Ministry of Russia
Russian Federation

Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training,

ul. Vorovskogo 64, Chelyabinsk, 454092


N. Yu. Kravchenko
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia$ State Budgetary City Teaching Hospital “City Clinical Hospital named after D.D.Pletnev of Healthcare Moscow City Department”
Russian Federation

Head of the Scientific and Methodological Center for Monitoring and Control of Respiratory Diseases, Orehovyy bul’var 28, Moscow, 115682;

Head of Respiratory Medicine Center, ul. Odinnadtsataya Parkovaya 32, Moscow, 105077


I. V. Leshchenko
Federal State Budget Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation; Ural Federal Research Institute of Phthisiology and Pulmonology – A Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia
Russian Federation

Doctor of Medicine, Professor, Department of Phthisiology and Pulmonology, ul. Repina 3, Ekaterinburg, 620028;

Chief Researcher, ul. 22-go Parts’ezda 50, Ekaterinburg, 620039


S. I. Ovcharenko
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation

Doctor of Medicine, Professor, Department No.1 of General Internal Medicine,

ul. Trubetskaya 8, build. 2, Moscow, 119991


A. I. Sinopal’nikov
Russian Medical Academy of Continuous Professional Education, Healthcare Ministry of Russian Federation
Russian Federation

Doctor of Medicine, Professor, Head of Department of Pulmonology, 

ul. Barrikadnaya 2/1, build. 1, Moscow, 123995


L. Ya. Frantsuzevich
V.A.Nasonova Federal Research Rheumatology Institute; Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University; Pirogov Russian National Research Medical University (Pirogov Medical University), Ministry of Health of the Russian Federation
Russian Federation

Pulmonologist, Kashirskoe shosse 34A, Moscow, 115522;

Intern Researcher, Department of Internal Medicine, Medical Research and Education Center, Leninskie gory 1, Moscow, 119991;

Assistant Lecturer, Department of Pulmonology, ul. Ostrovityanova 1, Moscow, 117997


References

1. Definition and classification of chronic bronchitis for clinical and epidemiological purposes: A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1965; 1 (7389): 775-779. https://doi.org/10.1016/S0140-6736(65)92953-3.

2. Braman S.S. Chronic cough due to chronic bronchitis: ACCP Evidence-Based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): 104S-115S. https://doi.org/10.1378/chest.129.1_suppl.104S.

3. Chernyaev A.L. [Pathomorphology of chronic obstructive bronchitis]. Russkiy meditsinskiy zhurnal. 1997; (17): 3-10. Available at: https://www.rmj.ru/articles/obshchie-stati/PATOMORFOLOGIYa_HRONIChESKOGO_OBSTRUKTIVNOGO_BRONHITA (in Russian).

4. Pallasaho P., Lundback B., Laspa S.L. et al. Increasing prevalence of asthma but not of chronic bronchitis in Finland? Report from the FinEsS-Helsinki Study. Respir. Med. 1999; 93 (11): 798-809. https://doi.org/10.1016/s0954-6111(99)90265-2.

5. Sobradillo V., Miravitlles M., Jimenez C.A. et al. Epidemiological study of chronic obstructive pulmonary disease in Spain (IBERPOC): prevalence of chronic respiratory symptoms and airflow limitation. Arch. Bronconeumol. 1999; 35 (4): 159-166. https://doi.org/10.1016/s0300-2896(15)30272-6.

6. Cerveri I., Accordini S., Verlato G. et al. European community respiratory health survey (ECRHS) study group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur. Respir. J. 2001; 18 (1): 85-92. https://doi.org/10.1183/09031936.01.00087101.

7. Janson C., Chinn S., Jarvis D., Burney P. Determinants of cough in young adults participating in the European Community Respiratory Health Survey. Eur. Respir. J. 2001; 18 (4): 647-654. https://doi.org/10.1183/09031936.01.00098701.

8. Huchon G.J., Vergnenegre A., Neukirch F. et al. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur. Respir. J. 2002; 20 (4): 806-812. https://doi.org/10.1183/09031936.02.00042002.

9. Miravitlles M., de la Roza C., Morera J. et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir. Med. 2006; 100 (11): 1973-1980. https://doi.org/10.1016/j.rmed.2006.02.024.

10. Pelkonen M., Notkola I.L., Nissinen A. et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006; 130 (4): 1129-1137. https://doi.org/10.1378/chest.130.4.1129.

11. de Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175 (1): 32-39. https://doi.org/10.1164/rccm.200603-381OC.

12. Miravitlles M., Soriano J.B., Garcia-Rio F. et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009; 64 (10): 863-868. https://doi.org/10.1136/thx.2009.115725.

13. Martinez C., Chen Y., Kazerooni E. et al. Non-obstructive chronic bronchitis in the COPDGene cohort. Am. J. Respir. Crit. Care Med. 2012; 185: 6622. https://doi.org/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A6622.

14. Kosarev V.V., Babanov S.A. [Social aspects of chronic bronchitis according to an epidemiological study]. Ekologiya cheloveka. 2005; (12): 46-49. Dostupno na: https://cyberleninka.ru/article/n/sotsialnye-aspekty-hronicheskogo-bronhita-po-dannym-epidemiologicheskogo-issledovaniya/viewer (in Russian).

15. International classification of diseases of the 10th revision. Available at: https://mkb-10.com (in Russian).

16. Smith J.A., Woodcock A. Chronic cough. N. Engl. J. Med. 2016; 375 (16): 1544-1551. https://doi.org/10.1056/NEJMcp1414215.

17. Terasaki G., Paauw D.S. Evaluation and treatment of chronic cough. Med. Clin. N. Am. 2014; 98 (3): 391-403. https://doi.org/10.1016/j.mcna.2014.01.002.

18. Achilleos A. Evidence-based evaluation and management of chronic cough. Med. Clin. North Am. 2016; 100 (5): 1033-1045. https://doi.org/10.1016/j.mcna.2016.04.008

19. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf

20. Dicpinigaitis P.V. Angiotensin-converting enzyme inhibitor-induced cough:ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): 169S-173S. https://doi.org/10.1378/chest.129.1_suppl.169S.

21. Pratter M.R. Overview of common causes of chronic cough. ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): 59S-62S. https://doi.org/10.1378/chest.129.1_suppl.59S.

22. Braman S.S. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): 104S-115S. https://doi.org/10.1378/chest.129.1_suppl.104S.

23. Celli B., MacNee W., ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur. Respir. J. 2004; 23 (6): 932-946. https://doi.org/10.1183/09031936.04.00014304.

24. Sinopal’nikov A.I., Klyachkina I.L. [Cough: Recommendations]. Moscow: Remedium; 2013 (in Russian).

25. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106 (2): 196-204. https://doi.org/10.7326/0003-4819-106-2-196.

26. Feeney A. S., Fendrick A. M., Quintiliani R. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am. J. Manag. Care. 2004; 10 (10): 689-696. Available at: https://www.ajmc.com/view/oct04-1903p689-696

27. Irwin R.S., French C.I., Chang A.B. et. al. Classification of cough as a symptom in adults and management algorithms. CHEST Guideline and Expert Panel Report. Chest. 2018; 153 (1): 196-209. https://doi.org/10.1016/j.chest.2017.10.016.

28. Shepelenko A.F. [Chronical bronchitis]. Trudnyy patsient. 2009; 7 (3): 33-38. Available at: https://cyberleninka.ru/article/n/hronicheskiy-bronhit/viewer (in Russian).

29. Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lover respiratory tract infections. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): 1-24. https://doi.org/10.1111/j.1469-0691.2011.03602.x.

30. Weis N., Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17 (2): 88-91. https://doi.org/10.1016/j.ejim.2005.09.020.

31. Amalakanti S., Pentakota M. R. Pulse oximetry overestimates oxygen saturation in COPD. Respir. Care. 2016; 61 (4): 423-427. https://doi.org/10.4187/respcare.04435.

32. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92 (4): 664-667. https://doi.org/10.1016/s0954-6111(98)90515-7.

33. Wielpütz M.O., Heußel C.P., Herth F.J., Kauczor H.U. Radiological diagnosis in lung disease: factoring treatment options into the choice of diagnostic modality. Dtsch. Arztebl. Int. 2014; 111 (11): 181. https://doi.org/10.3238/arztebl.2014.0181.

34. Agarwal R. L., Kumar D., Agarwal D.K.; Chabra G.S. Diagnostic values of electrocardiogram in chronic obstructive pulmonary disease (COPD). Lung India. 2008; 25 (2): 78. https://doi.org/10.4103/0970-2113.44125.

35. Chen M., Chen P., Zhong N. et al. The Chinese national guidelines on diagnosis and management of cough (December 2010). Chinese Med. J. 2011; 124 (20): 3207-3219. https://doi.org/10.3760/cma.j.issn.0366-6999.2011.20.002.

36. Lai K., Shen H., Zhou X. et al. Clinical practice guidelines for diagnosis and management of cough: Chinese Thoracic Society (CTS) asthma consortium. J. Thorac. Dis. 2018; 10 (11): 6314-6351. https://doi.org/10.21037/jtd.2018.09.153.

37. Irwin R.S. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129 (1, Suppl.): 80S-94S. https://doi.org/10.1378/chest.129.1_suppl.80S.

38. Hukkinen M., Korhonen T., Broms U. et al. Long-Term smoking behavior patterns predicting self-reported chronic bronchitis. J. COPD. 2009; 6 (4): 242-249. https://doi.org/10.1080/15412550903051781.

39. Pelkonen M. Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality. Cur. Opin. Pulm. Med. 2008; 14 (2): 105-109. https://doi.org/10.1097/MCP.0b013e3282f379e9.

40. Wynder E., Kaufman P., Lerrer R. et al. A short term follow up study on ex-cigarette smokers: with special emphasis on persistent cough and weight gain. Am. Rev. Respir. Dis. 1967; 96 (4): 645-655. https://doi.org/10.1164/arrd.1967.96.4.645.

41. Chandler M.A., Rennard S.I. Smoking cessation. Chest. 2010; 137 (2): 428-435. https://doi.org/10.1378/chest.09-0124.

42. Jorenby D.E., Leischow S.J., Nides M.A. et al. A controlled trial of sustained- release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340 (9): 685-691. https://doi.org/10.1056/NEJM199903043400903.

43. Faessel H., Ravva P., Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin. Ther. 2009; 31 (1): 177-189. https://doi.org/10.1016/j.clinthera.2009.01.003.

44. Willemse B.W.M., Postma D.S., Timens W., ten Hacken N.H.T. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur. Respir. J. 2004; 23 (3): 464-476. https://doi.org/10.1183/09031936.04.00012704.

45. Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV 1: The Lung Health Study. JAMA. 1994; 272 (19): 1497-1505. https://doi.org/10.1001/jama.1994.03520190043033.

46. Kardos P., Berck H., Fuchs K.H. et al. Guidelines of the German respiratory society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010; 64 (11): 701-711. https://doi.org/10.1055/s-0030-1255526.

47. Kardos P., Dinh Q.T., Fuchs K.H. et al. [Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute, subacute and chronic cough]. Pneumologie. 2019; 73 (3): 143-180. https://doi.org/10.1055/a-0808-7409 (in German).

48. Poole P., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (2): CD001287. https://doi.org/10.1002/14651858.CD001287.pub3.

49. Sevelius H., McCoy J.F., Colmore J.P. Dose response to codeine in patients with chronic cough. Clin. Pharmacol. Ther. 1971; 12 (3): 449-455. https://doi.org/10.1002/cpt1971123449.

50. Poole P., Sathananthan K., Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2019; (5): CD001287. https://doi.org/10.1002/14651858.CD001287.pub6.

51. Melloni B., Germouty J. [The influence of a new beta agonist: formoterol on mucociliary function]. Rev. Mal. Respir. 1992; 9 (5): 503-507 (in French).

52. Casaburi R., Mahler D., Jones P. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (2): 217-224. https://doi.org/10.1183/09031936.02.00269802.

53. Cazzola M., Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014; 10 (2): 110-120. https://doi.org/10.1183/20734735.014813.

54. Ghafouri R., Patil K., Kass I. Sputum changes associated with the use of ipratropium bromide. Chest. 1984; 86 (3): 387-393. https://doi.org/10.1378/chest.86.3.387.

55. Ram F., Jones P., Castro A. et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002: 2002 (2): CD003902. https://doi.org/10.1002/14651858.CD003902.

56. Lai K., Shen H., Zhou X. et al. Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium. J. Thorac. Dis. 2018; 10 (11): 6314-6351. https://doi.org/10.21037/jtd.2018.09.153.

57. Staykova T., Black P., Chacko E., Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst. Rev. 2003; (1): CD004105. https://doi.org/10.1002/14651858.CD004105.

58. El Moussaoui R., Roede B.M., Speelman P. et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008; 63 (5): 415-422. https://doi.org/10.1136/thx.2007.090613.

59. Adams S., Luther M. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest. 2000; 117 (5): 1345-1352. https://doi.org/10.1378/chest.117.5.1345.

60. Dimopoulos G., Siempos I.I., Korbila I.P. et al. Comparison of first line with secondline antibiotics for acute exacerba tions of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest. 2007; 132 (2): 447-455. https://doi.org/10.1378/chest.07-0149.

61. Giménez M., Aguilar L., Granizo J.J. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults. Multidiscip. Respir. Med. 2018; 13: 40. https://doi.org/10.1186/s40248-018-0152-5.

62. Miravitlles M., Espinosa C., Fernandez-Laso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest. 1999; 116 (1): 40-46. https://doi.org/10.1378/chest.116.1.40.

63. Sinopal’nikov A.I., Zaytsev A.A. [Antibacterial therapy for exacerbation of chronic obstructive pulmonary disease: focus on the duration of the “infection-free”period. Consilium Medicum. 2012; 14 (3): 74-78. Available at: https://consilium.orscience.ru/2075-1753/article/view/93587 (in Russian).

64. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29 (6): 1127-1137. https://doi.org/10.1183/09031936.00147806.

65. Falagas M., Avgeri S., Matthaiou D., Dimopoulos G. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 2008; 62 (3): 442-450. https://doi.org/10.1093/jac/dkn201.

66. Lorenz J., Steinfeld P., Drath L. et al. Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis. Clin. Drug Investig. 1998; 15 (1): 13-20. https://doi.org/10.2165/00044011-199815010-00002.

67. Sinopal’nikov A.I., Zaytsev A.A. [Compliance of patients with respiratory tract infections. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2008; 10 (1): 15-23. Available at: https://cmac-journal.ru/publication/2008/1/cmac-2008-t10-n1-p015 (in Russian).

68. Chodosh S., DeAbate C., Haverstock D. et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med. 2000; 94 (1): 18-27. https://doi.org/10.1053/rmed.1999.0708.

69. Masterton R., Burley C. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents. 2001; 18 (6): 503-512. https://doi.org/10.1016/s0924-8579(01)00435-6.

70. Higgings B.G., Powell R.M., Cooper S., Tattersfield A.E. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur. Respir. J. 1991; 4 (4): 415-420. Available at: https://erj.ersjournals.com/content/erj/4/4/415.full.pdf

71. Berton D.C., Reis M., Siqueira A.C. et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir. Med. 2010; 104 (9): 1288-1296. https://doi.org/10.1016/j.rmed.2010.05.017.

72. Tashkin D.P., Donohue J.F., Mahler D.A. et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 2009; 103 (4): 516-524. https://doi.org/10.1016/j.rmed.2008.12.014.

73. D’Urzo A., Rennard S., Kerwin E. et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir. Med. 2017; 125: 39-48. https://doi.org/10.1016/j.rmed.2017.02.008.

74. Pauwels R.A., Buist A.S., Calverley P.M. et al. GOLD scientific committee. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163 (5): 1256-1276. https://doi.org/10.1164/ajrccm.163.5.2101039.

75. Walters J. A. E. et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (9): CD001288. https://doi.org/10.1002/14651858.CD001288.pub4.

76. Leuppi J.D., Schuetz P., Bingisser R. et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309 (21): 2223-2231. https://doi.org/10.1001/jama.2013.5023

77. Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. N. Engl. J. Med. 1999; 340 (25): 1941-1947. https://doi.org/10.1056/NEJM199906243402502.

78. Rubin B.K. Mucolytics, expectorants, and mucokinetic medications. Respir. Care. 2007; 52 (7): 859-865. Available at: https://rc.rcjournal.com/content/52/7/859

79. Avdeev S.N., Vizel A. A., Abrosimo V.N. et al. Management of cough in patients with chronic obstructive pulmonary disease: results of the multicenter randomized placebo-controlled clinical trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 1243-1253. https://doi.org/10.2147/COPD.S292109.

80. Zaytsev A.A., Okovityy S.V. [Cough: differential diagnosis and rational pharmacotherapy. Terapevticheskiy arkhiv. 2014; 86 (12): 85-91. Available at: https://ter-arkhiv.ru/0040-3660/article/view/31635 (in Russian).

81. Nici L., Donner C., Wouters E. et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2006; 173 (12): 1390-1413. https://doi.org/10.1164/rccm.200508-1211ST.

82. Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: joint ACCP/AACVPR Evidence-Based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S-42S. https://doi.org/10.1378/chest.06-2418.

83. Mahler D.A. Pulmonary rehabilitation. Chest. 1998; 113 (4, Suppl.): 263S-268S. https://doi.org/10.1378/chest.113.4_supplement.263s.

84. Heffner J.E., Fahy B., Hilling L., Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am. J. Respir. Crit. Care Med. 1997; 155 (3): 1055-1059. https://doi.org/10.1164/ajrccm.155.3.9116986.

85. Heffner J.E., Fahy B., Hilling L., Barbieri C. Outcomes of advance directive education of pulmonary rehabilitation patients. Am. J. Respir. Crit. Care Med. 1997; 155 (3): 1055-1059. https://doi.org/10.1164/ajrccm.155.3.9116986.

86. Influenza vaccines: WHO position paper. Ezhenedel’nyy epidemiologicheskiy byulleten’. 2012, 87 (47): 461-476 (in Russian).

87. Grohskopf L.A., Olsen S.J., Sokolow L.Z. et al. Prevention and control of seasonal Influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2014-2015. MMWR Morb. Mortal. Wkly Rep. 2014; 63 (32): 691-697. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584910

88. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2013; (1): CD000422. https://doi.org/10.1002/14651858.CD000422.pub3.

89. Order of the Ministry of Health of the Russian Federation dated November 15, 2012 No.916n “On approval of the procedure for providing medical care to the population in the field of pulmonology”. Available at: https://rg.ru/2013/04/11/legkie-dok.html (in Russian).


Review

For citations:

Avdeev S.N., Demko I.V., Zaytsev A.A., Ignatova G.L., Kravchenko N.Yu., Leshchenko I.V., Ovcharenko S.I., Sinopal’nikov A.I., Frantsuzevich L.Ya. Federal guidelines on diagnosis and treatment of chronic bronchitis. PULMONOLOGIYA. 2022;32(3):448-472. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-3-448-472

Views: 11774


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)

The Publications Office Address
ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia
Tel.: 8-925-744-72-98
E-mail: pulmo@pulmonology.ru

Processing of personal data
supported by NEICON (Elpub lab)